

CLAIMS

What is claimed:

1. A compound represented by Formula (I):

5
$$X-A-Y-L-R \quad (I),$$

or a pharmaceutically acceptable salt thereof, wherein:


X and Y are each independently selected from optionally substituted aryl and optionally substituted heteroaryl;

A is selected from the group consisting of $-NHC(O)-$, , , and ;

10 L is $S(O)_2$, $S(O)$, S or O; and

R is connected to L via a carbon atom and is selected from the group consisting of optionally substituted $-C_1-C_{10}$ alkyl, optionally substituted $-C_2-C_{10}$ alkenyl, optionally substituted $-C_2-C_{10}$ alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted $-C_3-C_{12}$ cycloalkyl, optionally substituted $-C_3-C_{12}$ cycloalkenyl, and
 15 optionally substituted 3- to 12-membered heterocyclic.


2. The compound of claim 1, wherein R is $-C(R_{10})_3$,



20 independently selected from 0, 1, 2, or 3; v at each occurrence is independently selected from 1, 2, 3, or 4; T at each occurrence is independently selected from $C(R_{10})$ and N; E at each occurrence is independently selected from $-C(R_{10})_2-$, $-N(R_{10})-$, O, S, $S(O)$, and $S(O)_2$; R_{10} at each occurrence is independently selected from the group consisting of hydrogen, halo, $-CN$, $-NO_2$, optionally substituted $-C_1-C_6$ alkyl, optionally substituted $-C_2-C_8$ alkenyl, optionally substituted $-C_2-C_8$ alkynyl, optionally substituted $-C_3-C_8$ cycloalkyl,
 25 optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and $-L_1-R_1$; wherein L_1 is $-O-$, $-S-$, $-NR_1-$, $-C(O)-$, -


- C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; alternatively, two adjacent R₁₀ groups are taken together with the carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; two geminal R₁₀ groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or a spiro ring; and/or two remote R₁₀ groups are taken together with the atoms to which they are attached to form a bridging moiety.

3. The compound of claim 1, represented by Formula (IIIa), (IIIa-1), or (IIIa-2), or a pharmaceutically acceptable salt thereof:



- wherein each m is independently 0, 1, 2, 3 or 4; and R₁₄ at each occurrence is independently selected from the group consisting of hydroxy, protected hydroxy, halogen, -CN, -NO₂, optionally substituted amino, N₃, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, -C(O)₂-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)-C₁-C₆ alkyl.


4. The compound of claim 1, represented by Formula (IVa), (IVb), (IVc), (IVd), or (IVe) or a pharmaceutically acceptable salt thereof:



- wherein *m* at each occurrence is independently 0, 1, 2, 3 or 4; R₁₄ at each occurrence is independently selected from the group consisting of hydroxy, protected hydroxy, halogen, -CN, -NO₂, optionally substituted amino, N₃, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, -C(O)₂-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)-C₁-C₆ alkyl; *n* at each occurrence is independently selected from 0, 1, 2, or 3; T at each occurrence is independently selected from C(R₁₀) and N; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, , optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; alternatively, two adjacent R₁₀ groups are taken together with the


carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; two geminal R₁₀ groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or a spiro ring; and/or two remote R₁₀ groups are taken together with the atoms to which they are attached to form a bridging moiety.

5 The compound of claim 1, represented by Formula (Va), (Vb), (Vc), (Vd), or (Ve), or a pharmaceutically acceptable salt thereof:




- 10 wherein m₁ is 1, 2, or 3; m₂ is 1 or 2; m₃ is 0, 1, 2, or 3; R₂₁ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, and optionally substituted C₃-C₈ cycloalkyl; R₂₂ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, and optionally substituted -C₁-C₆ alkoxy;
- 15 n at each occurrence is independently selected from 0, 1, 2, or 3; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -
- 20

6. The compound of claim 1, represented by Formula (VIIa), (VIIb), (VIIc), (VIId), or (VIIe), or a pharmaceutically acceptable salt thereof:



15 wherein m1 is 1, 2, or 3; m3 is 0, 1, 2, or 3; R₂₁ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, and optionally substituted C₃-C₈ cycloalkyl; R₂₂ is selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, and optionally substituted -C₁-C₆ alkoxy; n at each occurrence is independently selected
20 from 0, 1, 2, or 3; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -


- C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; alternatively, two adjacent R₁₀ groups are taken together with the carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; two geminal R₁₀ groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or an additional spiro ring; and/or two remote R₁₀ groups are taken together with the atoms to which they are attached to form a bridging moiety.
7. The compound of claim 1, represented by Formula (VIIa-1), (VIIb-1), (VIIc-1), (VIId-1), or (VIIe-1), or a pharmaceutically acceptable salt thereof:



- wherein m₃ is 0, 1, 2, or 3; R₂₁ at each occurrence is independently selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, and optionally substituted C₃-C₈ cycloalkyl; R₂₂ is selected from the group consisting of halogen, CN, optionally substituted -C₁-C₆ alkyl, and optionally substituted -C₁-C₆ alkoxy; R₂₃ is selected from the group consisting of

- hydrogen, halogen, CN, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₁-C₆ alkoxy, and optionally substituted C₃-C₈ cycloalkyl; n at each occurrence is independently selected from 0, 1, 2, or 3; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the
- 5 group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at
- 10 each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally
- 15 substituted heteroaryl; alternatively, two adjacent R₁₀ groups are taken together with the carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; two geminal R₁₀ groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or an additional spiro ring; and/or two remote R₁₀ groups are taken together with the atoms to which they are attached to form a
- 20 bridging moiety.





8. The compound of claim 1, represented by Formula (VIIIa), (VIIIb), (VIIIc), or (VIId), or a pharmaceutically acceptable salt thereof:



- 25 wherein m at each occurrence is independently 0, 1, 2, 3 or 4; n at each occurrence is independently selected from 0, 1, 2, or 3; R₁₁ at each occurrence is independently selected from a group consisting of hydrogen, halogen, hydroxy, protected hydroxy, -CN, amino, protected amino, optionally substituted aryl, optionally substituted heteroaryl, optionally

- substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, optionally substituted -NH-C₁-C₆ alkyl, optionally substituted -N(C₁-C₆ alkyl)₂, -CO₂H, optionally substituted -C(O)₂-C₁-C₆ alkyl, optionally substituted -C(O)NH-C₁-C₆ alkyl, and optionally substituted -C(O)-C₁-C₆ alkyl; R₁₄ at each occurrence is independently selected from the groups consisting of hydroxy, protected hydroxy, halogen, -CN, -NO₂, optionally substituted amino, N₃, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, -C(O)₂-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)-C₁-C₆ alkyl; T at each occurrence is independently selected from C(R₁₀) and N; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; alternatively, two adjacent R₁₀ groups are taken together with the carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; two geminal R₁₀ groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or an additional spiro ring; and/or two remote R₁₀ groups are taken together with the atoms to which they are attached to form a bridging moiety.

9. The compound of claim 1, represented by Formula (VIIIa-1), (VIIIb-1), (VIIIc-1), or (VIId-1), or a pharmaceutically acceptable salt thereof:














- wherein m at each occurrence is independently 0, 1, 2, 3 or 4; n at each occurrence is independently selected from 0, 1, 2, or 3; R₁₁ at each occurrence is independently selected from a group consisting of hydrogen, halogen, hydroxy, protected hydroxy, -CN, amino, protected amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, optionally substituted -NH-C₁-C₆ alkyl, optionally substituted -N(C₁-C₆ alkyl)₂, -CO₂H, optionally substituted -C(O)₂-C₁-C₆ alkyl, optionally substituted -C(O)NH-C₁-C₆ alkyl, and optionally substituted -C(O)-C₁-C₆ alkyl; R₁₄ at each occurrence is independently selected from the groups consisting of hydroxy, protected hydroxy, halogen, -CN, -NO₂, optionally substituted amino, N₃, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted -C₁-C₆ alkoxy, -C(O)₂-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)-C₁-C₆ alkyl; E at each occurrence is independently selected from -C(R₁₀)₂-, -N(R₁₀)-, O, S, S(O), and S(O)₂; R₁₀ at each occurrence is independently selected from the group consisting of hydrogen, halo, -CN, -NO₂, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and -L₁-R₁; wherein L₁ is -O-, -S-, -NR₁-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R₁)-, -N(R₁)C(O)-, -OC(O)N(R₁)-, -N(R₁)C(O)O-, -N(R₁)C(O)N(R₁)-, -S(O)-, -S(O)₂-, -S(O)₂N(R₁)-, -N(R₁)S(O)₂-; R₁ at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted -C₁-C₆ alkyl, optionally substituted -C₂-C₈ alkenyl, optionally substituted -C₂-C₈ alkynyl, optionally substituted -C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic,












- optionally substituted aryl, and optionally substituted heteroaryl; alternatively, two adjacent R₁₀ groups are taken together with the carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; two geminal R₁₀ groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or an additional spiro ring; and/or two remote R₁₀ groups are taken together with the atoms to which they are attached to form a bridging moiety.












10. The compound of claim 1, selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:













10












Compound	Structure
1	
2	
3	
4	
5	
6	
7	












8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	










19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	











30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	











41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	











53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	











64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	











75	
76	
77	
78	
79	
80	
81	
82	
83	











84	
85	
86	
87	
88	
89	
90	
91	
92	
93	

94	
95	
96	
97	
98	
99	
100	
101	
102	
103	

104	
105	
106	
107	
108	
109	
110	
111	
112	
113	










114	
115	
116	
117	
118	
119	
120	
121	
122	
123	










124	
125	
126	
127	
128	
129	
130	
131	
132	
133	










134	
135	
136	
137	
138	
139	
140	
141	
142	
143	

144	
145	
146	
147	
148	
149	
150	
151	
152	
153	

154	
155	
156	
157	
158	
159	
160	
161	
162	
163	










164	
165	
166	
167	
168	
169	
170	
171	
172	

173	
174	
175	
176	
177	
178	
179	
180	
181	










182	
183	
184	
185	
186	
187	
188	
189	
190	










191	
192	
193	
194	
195	
196	
197	
198	
199	











200	
201	
202	
203	
204	
205	
206	
207	
208	

209	
210	
211	
212	
213	
214	
215	
216	
217	

218	
219	
220	
221	
222	
223	
224	
225	
226	










227	
228	
229	
230	
231	
232	
233	
234	
235	

236	
237	
238	
239	
240	
241	
242	
243	
244	

245	
246	
247	
248	
249	
250	
251	
252	
253	
254	









255	
256	
257	
258	
259	
260	
261	
262	
263	










264	
265	
266	
267	
268	
269	
270	
271	
272	
273	

274	
275	
276	
277	
278	
279	
280	
281	
282	










283	
284	
285	
286	
287	
288	
289	
290	
291	
292	










293	
294	
295	
296	
297	
298	
299	
300	
301	

302	
303	
304	
305	
306	
307	
308	
309	










310	
311	
312	
313	
314	
315	
316	
317	
318	










319	
320	
321	
322	
323	
324	
325	
326	
327	
328	

329	
330	
331	
332	
333	
334	
335	
336	
337	










338	
339	
340	
341	
342	
343	
344	
345	
346	










347	
348	
349	
350	
351	
352	
353	
354	
355	










356	
357	
358	
359	
360	
361	
362	
363	
364	

365	
366	
367	
368	
369	
370	
371	
372	
373	

374	
375	
376	
377	
378	
379	
380	
381	
382	

383	
384	
385	
386	
387	
388	
389	
390	
391	

392	
393	
394	
395	
396	
397	
398	
399	
400	

401	
402	
403	
404	
405	
406	
407	
408	
409	

410	
411	
412	
413	
414	
415	

11. A pharmaceutical composition, comprising a compound or a combination of compounds according to claim 1, in combination with a pharmaceutically acceptable carrier or excipient.

5

12. A method of treating or preventing an HBV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds according to claim 1.

10 13. The method of claim 12, further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of HBV polymerase inhibitors, interferon, viral entry inhibitors, viral maturation inhibitors, capsid assembly

or core protein inhibitors or modulators, reverse transcriptase inhibitors, TLR-agonists, inducers of cellular viral RNA sensor, therapeutic vaccines, RNA interference (RNAi) or small interfering RNA (siRNA) and combinations thereof.

5 14. The method of claim 13, wherein the compound and the at least one additional therapeutic agent are co-formulated.

15. The method of claim 13, wherein the at least one additional therapeutic agent is administered at a lower dose and/or frequency than that which is therapeutically effective
10 when said agent is administered alone.